{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:30:47Z","timestamp":1785180647851,"version":"3.55.0"},"reference-count":29,"publisher":"Walter de Gruyter GmbH","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2025-0264_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Macroprolactin (macro-PRL) mostly comprises a complex of PRL with IgG. The aim of this study was to clarify whether IgA-type macro-PRL exists and, if so, to elucidate the prevalence of and differences in laboratory data from IgG-type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0264_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>One hundred thirty patients with macroprolactinemia who were diagnosed through screening via the polyethylene glycol precipitation method followed by confirmation using gel filtration chromatography (GFC) were examined. IgA-type and IgG-type macro-PRLs were identified via Jacalin column\/SDS\u2012PAGE and protein G columns, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0264_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SDS\u2012PAGE under nonreducing conditions followed by western blotting with an IgA antibody revealed that the fraction bound to the Jacalin column was actually IgA. The PRL band was detected at the same position as the IgA band, which was purified with a Jacalin column, suggesting that PRL was bound to IgA. The finding that the PRL band was observed not only at the same position as IgA but also at the same position as the 23\u202fkDa PRL reference suggested that some PRL dissociated from IgA during SDS\u2012PAGE. The prevalence rates of macro-PRL of only IgA, IgA plus IgG, only IgG, and non-IgA\/non-IgG types were 7.7, 3.1, 83.8, and 5.4\u202f%, respectively. Neither the PEG precipitation ratios of PRL nor the macro-PRL ratios on GFC differed between IgA- and IgG-type macro-PRLs, whereas both ratios were significantly lower in non-IgA\/non-IgG-type macro-PRL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0264_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IgA-type macro-PRL was demonstrated to exist. IgG-type macro-PRL was most prevalent, followed by IgA, non-IgA\/non-IgG and IgA plus IgG-type macro-PRLs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2025-0264","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T01:12:57Z","timestamp":1744074777000},"page":"1728-1735","source":"Crossref","is-referenced-by-count":5,"title":["IgA-type macroprolactin among 130 patients with macroprolactinemia"],"prefix":"10.1515","volume":"63","author":[{"given":"Masayuki","family":"Ishihara","sequence":"first","affiliation":[{"name":"Department of Orthopedic Surgery , Kansai Medical University , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery , Kansai Medical University , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norito","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery , Kansai Medical University , Osaka , Japan"},{"name":"Department of Pharmacy , Kansai Medical University Hospital , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Aisaka","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , Hamada Hospital , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery , Kansai Medical University , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery , Kansai Medical University , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"2026051215061100379_j_cclm-2025-0264_ref_001","doi-asserted-by":"crossref","unstructured":"Fahie-Wilson, MN, Soule, SG. Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann Clin Biochem 1997;34:252\u20138. https:\/\/doi.org\/10.1177\/000456329703400305.","DOI":"10.1177\/000456329703400305"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_002","doi-asserted-by":"crossref","unstructured":"Leslie, H, Courtney, CH, Bell, PM, Hadden, DR, McCance, DR, Ellis, PK, et al.. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab 2001;86:2743\u20136. https:\/\/doi.org\/10.1210\/jcem.86.6.7521.","DOI":"10.1210\/jcem.86.6.7521"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_003","doi-asserted-by":"crossref","unstructured":"Vallette-Kasic, S, Morange-Ramos, I, Selim, A, Gunz, G, Morange, S, Enjalbert, A, et al.. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002;87:581\u20138. https:\/\/doi.org\/10.1210\/jcem.87.2.8272.","DOI":"10.1210\/jcem.87.2.8272"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_004","doi-asserted-by":"crossref","unstructured":"Gibney, J, Smith, TP, McKenna, TJ. Clinical relevance of macroprolactin. Clin Endocrinol 2005;62:633\u201343. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02243.x.","DOI":"10.1111\/j.1365-2265.2005.02243.x"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_005","doi-asserted-by":"crossref","unstructured":"Hattori, N, Ishihara, T, Saiki, Y. Macroprolactinaemia: prevalence and aetiologies in a large group of hospital workers. Clin Endocrinol 2009;71:702\u20138. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03570.x.","DOI":"10.1111\/j.1365-2265.2009.03570.x"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_006","doi-asserted-by":"crossref","unstructured":"Fahie-Wilson, MN, John, R, Ellis, AR. Macroprolactin; high molecular mass forms of circulating prolactin. Ann Clin Biochem 2005;42:175\u201392. https:\/\/doi.org\/10.1258\/0004563053857969.","DOI":"10.1258\/0004563053857969"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_007","doi-asserted-by":"crossref","unstructured":"Fahie-Wilson, MN, Cobbaert, CM, Horvath, AR, Smith, TP. Interference by macroprolactin in assays for prolactin: will the in\u00a0vitro diagnostics regulation lead to a solution at last? Clin Chem Lab Med 2022;60:1350\u20135. https:\/\/doi.org\/10.1515\/cclm-2022-0460.","DOI":"10.1515\/cclm-2022-0460"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_008","doi-asserted-by":"crossref","unstructured":"Soh, NAAC, Yaacob, NM, Omar, J, Jelani, AM, Shafii, N, Ismail, TST, et al.. Global prevalence of macroprolactinemia among patients with hyperprolactinemia: a systematic review and meta-analysis. Int J Environ Res Publ Health 2020;17:8199. https:\/\/doi.org\/10.3390\/ijerph17218199.","DOI":"10.3390\/ijerph17218199"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_009","doi-asserted-by":"crossref","unstructured":"Hattori, N, Inagaki, C. Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G complex. J Clin Endocrinol Metab 1997;82:3107\u201310. https:\/\/doi.org\/10.1210\/jcem.82.9.4250.","DOI":"10.1210\/jc.82.9.3107"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_010","doi-asserted-by":"crossref","unstructured":"Hattori, N, Nakayama, Y, Kitagawa, K, Ishihara, T, Saiki, Y, Inagaki, C. Anti-prolactin (PRL) autoantibodies suppress PRL bioactivity in patients with macroprolactinaemia. Clin Endocrinol 2008;68:72\u20136. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.03001.x.","DOI":"10.1111\/j.1365-2265.2007.03001.x"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_011","doi-asserted-by":"crossref","unstructured":"Lea\u00f1os-Miranda, A, C\u00e1rdenas-Mondrag\u00f3n, G, Rivera-Lea\u00f1os, R, Ulloa-Aguirre, A, Goffin, V. Application of new homologous in\u00a0vitro bioassays for human lactogens to assess the actual bioactivity of human prolactin isotypes in hyperprolactinaemic patients. Clin Endocrinol 2006;65:146\u201353.","DOI":"10.1111\/j.1365-2265.2006.02548.x"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_012","doi-asserted-by":"crossref","unstructured":"Schiettecatte, J, De Schepper, J, Velkeniers, B, Smitz, J, Van Steirteghem, A. Rapid detection of macroprolactin in the form of prolactin-immunoglobulin G complexes by immunoprecipitation with anti-human IgG-agarose. Clin Chem Lab Med 2001;39:1244\u20138. https:\/\/doi.org\/10.1515\/cclm.2001.200.","DOI":"10.1515\/CCLM.2001.200"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_013","doi-asserted-by":"crossref","unstructured":"De Schepper, J, Schiettecatte, J, Velkeniers, B, Blumenfeld, Z, Shteinberg, M, Devroey, P, et al.. Clinical and biological characterization of macroprolactinemia with and without prolactin-IgG complexes. Eur J Endocrinol 2003;149:201\u20137. https:\/\/doi.org\/10.1530\/eje.0.1490201.","DOI":"10.1530\/eje.0.1490201"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_014","doi-asserted-by":"crossref","unstructured":"Lippi, G, Plebani, M. Macroprolactin: searching for a needle in a haystack? Clin Chem Lab Med 2016;54:519\u201322. https:\/\/doi.org\/10.1515\/cclm-2015-1283.","DOI":"10.1515\/cclm-2015-1283"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_015","doi-asserted-by":"crossref","unstructured":"Mills, F, Jeffery, J, Mackenzie, P, Cranfield, A, Ayling, RM. An immunoglobulin G complexed form of thyroid-stimulating hormone (macro thyroid-stimulating hormone) is a cause of elevated serum thyroid-stimulating hormone concentration. Ann Clin Biochem 2013;50:416\u201320. https:\/\/doi.org\/10.1177\/0004563213476271.","DOI":"10.1177\/0004563213476271"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_016","doi-asserted-by":"crossref","unstructured":"Yamada, A, Hattori, N, Matsuda, T, Nishiyama, N, Shimatsu, A. Clearance of macro-TSH from the circulation is slower than TSH. Clin Chem Lab Med 2022;60:e132\u20135. https:\/\/doi.org\/10.1515\/cclm-2022-0131.","DOI":"10.1515\/cclm-2022-0131"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_017","doi-asserted-by":"crossref","unstructured":"Biondi, B, Cooper, DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008;29:76\u2013131. https:\/\/doi.org\/10.1210\/er.2006-0043.","DOI":"10.1210\/er.2006-0043"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_018","doi-asserted-by":"crossref","unstructured":"Spitz, IM, Le Roith, D, Hirsch, H, Carayon, P, Pekonen, F, Liel, Y, et al.. Increased high-molecular-weight thyrotropin with impaired biologic activity in a euthyroid man. N Engl J Med 1981;304:278\u201382. https:\/\/doi.org\/10.1056\/nejm198101293040506.","DOI":"10.1056\/NEJM198101293040506"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_019","doi-asserted-by":"crossref","unstructured":"Hattori, N, Ishihara, T, Yamagami, K, Shimatsu, A. Macro TSH in patients with subclinical hypothyroidism. Clin Endocrinol 2015;83:923\u201330. https:\/\/doi.org\/10.1111\/cen.12643.","DOI":"10.1111\/cen.12643"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_020","unstructured":"Nkuna, X, Dire, Z, Khoza, S. A macro-TSH: a clinical diagnostic dilemma. J Int Fed Clin Chem Lab Med 2022;33:317\u201324."},{"key":"2026051215061100379_j_cclm-2025-0264_ref_021","doi-asserted-by":"crossref","unstructured":"Fukushita, M, Watanabe, N, Noh, JY, Yoshihara, A, Matsumoto, M, Suzuki, N, et al.. A case of macro-TSH consisting of IgA-bound TSH. Endocr J 2021;68:1241\u20136.","DOI":"10.1507\/endocrj.EJ21-0021"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_022","doi-asserted-by":"crossref","unstructured":"Hattori, N, Aisaka, K, Shimatsu, A. A possible cause of the variable detectability of macroprolactin by different immunoassay systems. Clin Chem Lab Med 2016;54:603\u20138. https:\/\/doi.org\/10.1515\/cclm-2015-0484.","DOI":"10.1515\/cclm-2015-0484"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_023","doi-asserted-by":"crossref","unstructured":"Roque-Barreira, MC, Campos-Neto, A. Jacalin: an IgA-binding lectin. J Immunol 1985;134:1740\u20133. https:\/\/doi.org\/10.4049\/jimmunol.134.3.1740.","DOI":"10.4049\/jimmunol.134.3.1740"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_024","doi-asserted-by":"crossref","unstructured":"Bonhoff, A, Vuille, JC, Gomez, F, Gellersen, B. Identification of macroprolactin in a patient with asymptomatic hyperprolactinemia as a stable PRL-IgG complex. Exp Clin Endocrinol Diabetes 1995;103:252\u20135. https:\/\/doi.org\/10.1055\/s-0029-1211358.","DOI":"10.1055\/s-0029-1211358"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_025","doi-asserted-by":"crossref","unstructured":"Hattori, N. The frequency of macroprolactinemia in pregnant women and the heterogeneity of its etiologies. J Clin Endocrinol Metab 1996;81:586\u201390. https:\/\/doi.org\/10.1210\/jcem.81.2.8636272.","DOI":"10.1210\/jc.81.2.586"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_026","doi-asserted-by":"crossref","unstructured":"Nguyen, KQN, Langevin, RH, McPhaul, MJ, Hashim, IA. Circulating macroprolactin exhibits molecular heterogeneity and is not exclusively an antibody complex. Clin Chim Acta 2021;514:90\u20135.","DOI":"10.1016\/j.cca.2020.12.018"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_027","doi-asserted-by":"crossref","unstructured":"Carlson, HE, Markoff, E, Lee, DW. On the nature of serum prolactin in two patients with macroprolactinemia. Fertil Steril 1992;58:78\u201387. https:\/\/doi.org\/10.1016\/s0015-0282(16)55140-1.","DOI":"10.1016\/S0015-0282(16)55140-1"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_028","doi-asserted-by":"crossref","unstructured":"Gleeson, PJ, Camara, NOS, Launay, P, Lehuen, A, Monteiro, RC. Immunoglobulin A antibodies: from protection to harmful roles. Immunol Rev 2024;328:171\u201391. https:\/\/doi.org\/10.1111\/imr.13424.","DOI":"10.1111\/imr.13424"},{"key":"2026051215061100379_j_cclm-2025-0264_ref_029","doi-asserted-by":"crossref","unstructured":"Chi, X, Li, Y, Qiu, X. V(D)J recombination, somatic hypermutation and class switch recombination of immunoglobulins: mechanism and regulation. Immunology 2020;160:233\u201347. https:\/\/doi.org\/10.1111\/imm.13176.","DOI":"10.1111\/imm.13176"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0264\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0264\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:08:24Z","timestamp":1778598504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0264\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,1]]},"published-print":{"date-parts":[[2025,8,26]]}},"alternative-id":["10.1515\/cclm-2025-0264"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-0264","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]}}}